Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
32 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | recruiting | Phase 1 | 120 | Biocon Biologics UK PLCINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT05262400 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 235 | PfizerINDUSTRY | 9 | Sep 14, 2026 |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06334991 | Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 20 | ImmunityBio, Inc.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT05017012 | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) | completed | Phase 1 | 142 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jun 5, 2026 | clinicaltrials |
| NCT04305054 | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 14 | May 28, 2026 | clinicaltrials |
| NCT06879041 | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 136 | AstraZenecaINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT04597411 | Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 101 | EndocyteINDUSTRY | 2 | Apr 30, 2026 | clinicaltrials |
| NCT02138734 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 369 | ImmunityBio, Inc.INDUSTRY | 3 | Mar 31, 2026 | clinicaltrials |
| NCT05502367 | A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia | terminated | Phase 1 / Phase 2 | 44 | Antiva BiosciencesINDUSTRY | 3 | Feb 19, 2026 | clinicaltrials |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Oct 28, 2025 | clinicaltrials |
| NCT03564691 | Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | completed | Phase 1 | 470 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Oct 7, 2025 | clinicaltrials |
| NCT04480619 | Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients(Shiva) | not yet recruiting | Phase 1 / Phase 2 | 25 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Jul 16, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT03665597 | Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) | completed | Phase 1 | 138 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Feb 10, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT05303376 | Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness | completed | Phase 1 / Phase 2 | 123 | Immune Biosolutions IncINDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03697226 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | completed | Phase 1 | 8 | Antiva BiosciencesINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01765543 | A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) | completed | Phase 1 | 27 | Hoffmann-La RocheINDUSTRY | 5 | Dec 15, 2016 | clinicaltrials |
| NCT01765569 | A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 29 | Hoffmann-La RocheINDUSTRY | 5 | Sep 23, 2015 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT01697020 | Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions | completed | Phase 1 | 70 | Nova Laboratories LimitedINDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials